Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Rating of “Moderate Buy” by Brokerages

Health Catalyst, Inc. (NASDAQ:HCAT) has been given an average rating of “Moderate Buy” by the twelve research firms that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.71.

HCAT has been the topic of a number of research reports. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Stephens upped their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Piper Sandler lowered their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Finally, Citigroup boosted their price objective on Health Catalyst from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

Health Catalyst Trading Up 6.1 %

NASDAQ:HCAT opened at $8.13 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market cap of $494.71 million, a PE ratio of -6.02 and a beta of 1.32. The stock’s 50-day moving average is $8.13 and its two-hundred day moving average is $7.27. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the company posted ($0.22) earnings per share. The company’s revenue was up 3.5% compared to the same quarter last year. As a group, equities research analysts forecast that Health Catalyst will post -0.35 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In other news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $7.70, for a total transaction of $40,109.30. Following the sale, the chief operating officer now owns 129,690 shares in the company, valued at approximately $998,613. This represents a 3.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,068 shares of company stock valued at $257,555 over the last quarter. 2.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. raised its position in shares of Health Catalyst by 6.9% during the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after acquiring an additional 1,907 shares during the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after purchasing an additional 2,064 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Health Catalyst by 10.3% in the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after purchasing an additional 2,164 shares during the last quarter. Creative Planning lifted its stake in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after buying an additional 2,486 shares during the period. Finally, Quarry LP boosted its holdings in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.